Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETC-1907206 and dasatinib in advanced haematologic malignancies
NCT03414450Phase 1Withdrawn
- Sponsor
- Experimental Drug Development Centre
- Start
- Apr 2018
- Primary completion
- Feb 2022
- Countries
- 2
01
Overview
Phase 1, open-label trial of tinodasertib in Acute lymphoblastic leukemia, Philadelphia chromosome positive, acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and 1 more (2 arms), sponsored by Experimental Drug Development Centre. Primary endpoints: Maximum Tolerated Dose at 28 days, Incidence of Adverse Events at 44 months and 8 more. Planned start Apr 2018; status: withdrawn.
02
Drugs
tinodasertib
03
Conditions
Acute lymphoblastic leukemia, Philadelphia chromosome positiveacute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)chronic myeloid leukemia blast crisis (CML-BC)
Beyond the preview
Go deeper on NCT03414450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03414450.